Skip to main content
logo
SpyGlass Pharma, Inc. (SGP)
NASDAQ: SGP · Real-Time Price · USD
25.78
-0.42 (-1.60%)
Aug 17, 2026, 4:00 PM EDT - Market closed

SpyGlass Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-56.05-39.87-29.16
Depreciation & Amortization
1.010.610.27
Loss (Gain) From Sale of Assets
00.01-
Stock-Based Compensation
5.612.791.49
Other Operating Activities
-0.261.324.04
Change in Accounts Receivable
-0.13-0.01-0.3
Change in Accounts Payable
1.450.551.34
Change in Other Net Operating Assets
1.811.910.3
Operating Cash Flow
-46.56-32.7-22.03
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-3.18-0.79-1.99
Investment in Securities
-11-11.0124.25
Investing Cash Flow
-14.18-11.7922.26

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Issuance of Common Stock
0.150.170.19
Repurchase of Common Stock
--1.45-
Other Financing Activities
-3.93-1.47-
Financing Cash Flow
156.64124.590.19

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
95.9180.090.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-49.74-33.49-24.02
Free Cash Flow Growth
---
Free Cash Flow Per Share
-3.44-15.11-13.43
Levered Free Cash Flow
--22.24-
Unlevered Free Cash Flow
--22.24-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash Income Tax Paid
-00.02
Change in Working Capital
3.122.451.34
SEC Filings: 10-K · 10-Q